Meeting
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
The SAINT: Initial results of a phase I/II study of safety/efficacy using safe amounts of ipilimumab, nivolumab, and trabectedin as first-line treatment of advanced soft tissue sarcoma.
Authors
Sant P. Chawla
Sarcoma Oncology Center, Santa Monica, CA
Sant P. Chawla, Victoria S. Chua-Alcala, Katherine Kim, Nupur Assudani, Ahmad Al-Shihabi, Ania Moradkhani, Doris Quon, Steven Wong, William W. Tseng, Seth Pollack, Amor M. Srikureja, John Jalas, Robin Lewis Jones, Erlinda Maria Gordon
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Breast and Gynecologic Cancers,Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Hematologic Malignancies
Sub Track
Special Populations
Clinical Trial Registration Number
NCT03138161
Citation
J Clin Oncol 37, 2019 (suppl 8; abstr 22)
DOI
10.1200/JCO.2019.37.8_suppl.22
Abstract #
22
Poster Bd #
B6
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Phase 1/2 study of safety/efficacy using trabectedin, ipilimumab and nivolumab triple therapy as first line treatment of advanced soft tissue sarcoma.
First Author: Erlinda Maria Gordon
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Phase 1/2 study of safety/efficacy using trabectedin, ipilimumab, and nivolumab as first-line treatment of advanced soft tissue sarcoma (STS).
First Author: Erlinda Maria Gordon
Poster
2019 ASCO Annual Meeting
SAINT: Results of a phase 1/2 study of safety/efficacy using safe amounts of ipilimumab, nivolumab, and trabectedin as first-line treatment of advanced soft tissue sarcoma.
First Author: Erlinda Maria Gordon
Poster
2022 ASCO Annual Meeting
Five-year results of a phase 2 trial using ipilimumab (I), nivolumab (N), and trabectedin (T) for previously untreated advanced soft tissue sarcoma (NCT03138161).
First Author: Erlinda Maria Gordon